Singapore/Mumbai, September 11, 2019 – Everlife Holdings Pte. Ltd. (Everlife), a leading distributor and manufacturer of medical and laboratory equipment and devices in Asia—announced today the appointment of Raman Gandotra as its new CEO. Based out of Singapore, Raman will lead the platform through its next stage of growth which will focus on continuing to deliver superior performance for its principals, further strengthening the company’s position in core markets and priority segments through acquisitions and realising synergies across our portfolio of companies.
Raman brings with him over 25 years of experience, with a proven track record in building effective teams and driving growth for leading industry players in the pharmaceutical and medical devices sectors.
Prior to joining Everlife, Raman was leading the India and South-East Asia business of Smith & Nephew, a global leader in surgical equipment, orthopaedics and wound care. Raman and his team built strong growth, sustainably gaining shares across businesses in five years while increasing margins. He led disciplined customer segmentation and targeting, driving operational excellence initiatives across countries, creating effective engagement strategies with distribution partners and continuing to introduce innovative products that improve healthcare outcomes for patients. Prior to Smith & Nephew, Raman held leadership roles in India and South-East Asia at Baxter and Allergan.
“Raman is very well-positioned to take the helm of Everlife, given his experience, skills and his action-oriented leadership style. The Board and I have strong confidence in his ability to identify and deliver on opportunities to drive growth, strengthen our operational cadence and cement our position in the region as a leader in our space.” said Arjun Oberoi, Vice Chairman of the Board, Everlife and Managing Director, Everstone Capital.
“I am excited to join Everlife at this pivotal point in the company’s evolution. Everlife has already emerged as a leader in the laboratory, medical equipment and devices space in Asia. I look forward to leading the next phase of Everlife’s journey through its expansion in new geographies and product segments and adopting new tools and technologies to bring superior value to our customers.” said Raman Gandotra on joining the Everlife team.
Everlife has investments in CPC Diagnostics, an India based manufacturer and marketer of in-vitro diagnostic products; Malaysia-based Chemopharm Group, a leading provider of products and solutions to laboratory, research and medical facilities in South-East Asia; DV Medika Group, manufacturer and distributor of one of Indonesia’s top brands of hospital furniture and other imported medical equipment and supplies; and Singapore-based Bio-REV Pte. Ltd., which specializes in distribution of reagents, media and consumables to the Life Sciences industry.
About Everlife Holdings Pte Ltd
Everlife Holdings Pte. Ltd. is a buy-and-build platform aimed to provide complete solutions for the healthcare and research industries in South East Asia and India. As part of the Everstone Group, Everlife invests in manufacturers and distributors in the region covering key strategic segments including in-vitro diagnostics, medical diagnostics, critical care equipment, implants and consumables. Cure Capital is a minority investor in Everlife. Everlife’s portfolio companies represent more than 200 principals and its more than 600 employees operate in seven countries. For more information, visit www.everlifeasia.com.
About Everstone Group
Everstone is a premier investment group focused on India and South East Asia, with assets in excess of US$5 billion across private equity, real estate, green infrastructure and venture capital. Everstone has a significant resource base across its seven offices in Singapore, India (Mumbai, Delhi, Bangalore), London, New York and Mauritius, comprising best-of-breed investing, operations and strategic resources with significant experience and skills. For more information, visit www.everstonecapital.com